Pulmonx Reports 6% Q3 Revenue Growth, Narrows Loss And Maintains 2026 Revenue Outlook

Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, with net loss narrowing to $8.4M. Gross margin improved to 76%. The company maintained its 2026 revenue outlook of $90M-$92M and expects full-year gross margin of 77%. U.S. and international revenues both increased, with international growth affected by China's distributor restart.

Original reporting
Published Oct 29, 2026, 3:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 3:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LUNG
Bullish
medium confidence
Mentioned
$LUNG
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$LUNGBullishMed
01

Why it matters

The quarter shows a return to year-over-year revenue growth and meaningful expense reduction, while management maintained the 2026 revenue range and provided gross margin and operating expense expectations.

02

Market read

Traders can reassess near-term risk/reward based on fresh quarterly performance and whether the China restart and cost realignment continue to translate into sustained revenue growth and further loss narrowing.

03

What to watch

China restart timing and the renewed commercial activity after registration certificate renewal could create volatility in subsequent quarters; also, operating expense guidance includes non-cash stock-based compensation, which may affect how investors judge underlying cash profitability.

Relevance 8/10Novelty 7/10Timing: post-market/afternoon report on 2026 Q3 results and reiterated 2026 outlook

Background

Pulmonx is a medical device company reporting Q3 2026 results, including revenue growth, margin improvement, and cost realignment efforts.

Company-level read

Ticker impact

$LUNGBullishMedium confidence
Context

Pulmonx reported Q3 2026 revenue of $22.8M (+6% YoY), narrowed net loss, and maintained 2026 revenue outlook of $90M-$92M.

Expected impact

Likely upward bias as investors price in stabilization of revenue growth and narrowing losses, with follow-through dependent on whether China restart and expense discipline sustain.

Evidence & confidence

The article provides fresh quarterly datapoints (revenue growth, margin, expense decline, loss narrowing) plus reiterated full-year revenue and margin/expense expectations, which typically supports near-term sentiment even without guidance raise.

Market effects

Adds incremental signal of demand and cost discipline for respiratory medical device peers, but no direct sector-wide catalyst is disclosed.

China distributor absence is cited as a driver of international growth variability, highlighting regional execution risk for medtech revenue.

Primarily company-specific; no broader macro or regulatory shift is mentioned.

Counterpoint

Unchanged full-year revenue guidance suggests the market may already expect stabilization, so the stock reaction could fade if investors focus on cash burn and the $22M expected full-year cash decrease.

Key entities

  • Pulmonx Corporation

    Reported Q3 2026 revenue growth, narrowed losses, and reiterated full-year 2026 revenue outlook.

  • Glen French

    CEO who attributed plans to commercial execution, clinical initiatives, and realigned cost structure.

Related articles

$LUNGMed

Pulmonx Corporation: Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal System

Pulmonx Corporation (Nasdaq: LUNG) announced the publication of CONVERT Trial results for its AeriSeal System, showing 75.8% of patients with severe emphysema and collateral ventilation had successful treatment. The study suggests the system could enable subsequent treatment with Zephyr Valves, improving lung function and quality of life. Pulmonx is now conducting the CONVERT II Pivotal Trial to support a U.S. FDA Premarket Approval application for the AeriSeal System.

$LUNGMed

Pulmonx reports trial results for emphysema treatment system

Pulmonx (LUNG) reported CONVERT Trial results for its AeriSeal System in severe emphysema patients, showing 75.8% success in converting collateral ventilation status. Treated patients achieved 88.9% target lobe volume reduction at 45 days, with improvements in lung function and quality of life. The company is enrolling patients in the CONVERT II Pivotal Trial for U.S. FDA approval.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$LUNGHigh

Pulmonx (LUNG) Q3 2026 Earnings Call Transcript

Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.